Atrial fibrillation (AF) is a condition where the heart beats irregularly and often too fast. The RESOLVE-AF study is testing a special tool, the Ablacath™ Mapping Catheter, and a system called Ablamap® to help doctors better treat AF. This study looks at how well these tools work for different types of AF, like paroxysmal (short episodes) or persistent (lasts longer), and if they make the treatment safer. The study will follow participants for 12 months to see how well they do after using the mapping system to guide their treatment.
- The study will include up to 400 people at 25 locations worldwide.
- Participants must be at least 18 years old and good candidates for heart mapping and treatment.
- Participants cannot join if they have certain heart conditions, recent heart surgery, or other serious health issues.
Key Points:
- This study involves heart mapping and ablation therapy.
- Participants will be followed for a year after the procedure.
- People with certain health conditions cannot join this study.
How understandable was the trial content above?
Hard to understand
Easy to understand